ISB2001

Cat. No.: HY-P991490 Purity: 99.17%: Data Sheet
COA

SDS

FAQs
Technical Support

ISB2001 is a trispecific antibody targeting CD38, CD3 and BCMA. ISB2001 effectively counteracts tumor immune escape mechanisms caused by antigen downregulation, antigen loss, soluble factor competition and other factors. ISB2001 is applicable to relevant research on multiple myeloma and relapsed/refractory multiple myeloma.

For research use only. We do not sell to patients.

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All TNF Receptor Isoform Specific Products:

View All Isoforms

TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF10B/DR5/CD262 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG1 kappa-Fab

Recommend Isotype Controls

Human IgG1 kappa, Isotype Control

Species Reactivity

Human

IC₅₀ & Target

CD38 & CD3 & BCMA

In Vitro

ISB2001 exhibits potent, affinity-driven tumor cell killing activity across multiple multiple myeloma (MM) cell lines, with subpicomolar EC₅₀ values^[2].
ISB2001 remains active against MM cells with single antigen loss, and can overcome the antigen escape mechanism that limits single antigen-targeted therapies^[2].
ISB2001 is minimally affected by soluble factors (sBCMA, APRIL, sCD38) present in the serum of multiple myeloma (MM) patients, with only a 30-fold increase in its EC₅₀; in contrast, the EC₅₀ of BCMA-targeting TCEs increases to a significantly greater extent^[2].
ISB2001 (0.01-1 nM) exhibits superior cytotoxicity against primary multiple myeloma (MM) cells derived from bone marrow aspirates and peripheral blood, inducing significant ⁺ CD138 tumor cell killing and CD8⁺ T cell activation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ISB2001 (0.02-0.5 mg/kg, intravenous injection, once weekly for 3 consecutive weeks) induces significant dose-dependent tumor growth inhibition and complete regression in the KMS-12-BM multiple myeloma xenograft model, accompanied by activation of tumor-infiltrating CD8⁺ T cells and increased levels of local proinflammatory cytokines^[2].
ISB2001 (0.02-0.5 mg/kg, intravenous injection, once weekly for 3 consecutive weeks) induces significant, dose-dependent tumor growth inhibition and complete regression in the NCI-H929 multiple myeloma xenograft model^[2].
ISB2001 (0.1-1 mg/kg; subcutaneous injection; once weekly for 3 consecutive weeks) induces complete tumor regression in all humanized HIS-NXG mice treated with 1 mg/kg, and elicits partial persistent rejection responses in mice treated with 0.1 mg/kg^[2].
ISB2001 (1.5 mg/kg; subcutaneous injection; single administration) does not induce depletion of CD38-expressing bone marrow hematopoietic progenitor cells or lymphoid cells in humanized HIS-NXG mice, exhibiting favorable on-target off-tumor safety profiles^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) (female, 6-7 weeks old)^[2]
Dosage:	0.02 mg/kg; 0.1 mg/kg; 0.5 mg/kg
Administration:	i.v.; once weekly; 3 weeks
Result:	Induced significant tumor growth control relative to vehicle at all doses. Induced complete tumor regression in all treated mice at 0.5 mg/kg and 0.1 mg/kg. Induced partial efficacy with reduced tumor growth compared to vehicle at 0.02 mg/kg. Elevated tumor-infiltrating CD8⁺ T cell expression of CD69 (84.3% positive cells) and CD25 (45.6% positive cells) two days after treatment, compared to vehicle-treated mice (2.8% CD69⁺, 0.0% CD25⁺) and CD3×DU×DU-treated mice (13.0% CD69⁺, 0.0% CD25⁺). Elevated concentrations of IFNγ (mean 100-250 ng/g tumor) and TNF (mean 1000-2500 pg/g tumor) in tumor supernatants, with no significant systemic cytokine activation.

Animal Model:	NCG (NOD-Prkdcem26Cd52Il2rgem26Cd22/NjuCrl) (female, 6-7 weeks old)^[2]
Dosage:	0.02 mg/kg; 0.1 mg/kg; 0.5 mg/kg
Administration:	i.v.; once weekly; 3 weeks
Result:	Induced significant tumor growth control at all tested doses relative to vehicle. Induced complete tumor regression in all treated mice at 0.5 mg/kg and 0.1 mg/kg. Induced partial tumor growth inhibition at 0.02 mg/kg.

Animal Model:	HIS-NXG (human immunized system-NOD-Prkdcscid-IL2rgTm1/Rj, reconstituted with human cord blood CD34⁺ cells) (female, 24-30 weeks old)^[2]
Dosage:	0.1 mg/kg; 1 mg/kg
Administration:	s.c.; once weekly; 3 weeks
Result:	Induced complete tumor regression in all mice treated with 1 mg/kg. Induced a treatment response in all mice treated with 0.1 mg/kg, with 4 out of 9 mice achieving durable tumor rejection; remaining mice with palpable tumors showed greatly reduced tumor regrowth kinetics compared to vehicle-treated mice.

Application

ELISA, FACS, Functional assay

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

169.15 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[ISB2001]

Shipping

Shipping with dry ice.

Formulation

Please refer to the lot-specific COA for specific buffer information.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Format

Human IgG1 kappa-FAB

Biological Activity

Loaded ISB2001 on ProA biosensor, can bind Human BCMA/TNFRSF17 Protein, His Tag with an affinity constant of 1.30E-10 M as determined in BLI assay.
Loaded ISB2001 on ProA biosensor, can bind Human CD3 epsilon & CD3 delta Heterodimer Protein, His Tag&Tag Free with an affinity constant of 3.03E-08 M as determined in BLI assay.
Loaded ISB2001 on ProA biosensor, can bind CD38-Avi tag His with an affinity constant of 9.09E-09 M as determined in BLI assay.

Purity & Documentation

Purity: 99.17%

Select Batch:

Data Sheet (264 KB) SDS (251 KB)

COA (232 KB) SDS-PAGE (62 KB) SEC-HPLC (103 KB)

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Quach H, et al. First results of a phase 1, first-in-human, dose escalation study of ISB 2001, a BCMAxCD38xCD3 targeting trispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2024 Nov 5;144:1026.

[2]. Carretero-Iglesia L, et al. ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells. Nat Cancer. 2024;5(10):1494-1514. [Content Brief]

ISB2001 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *